초록 ▼

Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use o

Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed.

대표청구항 ▼

What is claimed is: 1. A composition comprising: a) a yeast vehicle; and b) a fusion protein expressed by the yeast vehicle, the fusion protein comprising: i) at least one cancer antigen or immunogenic domain thereof; and ii) a peptide linked to the N-terminus of the cancer antigen or immunogenic d

What is claimed is: 1. A composition comprising: a) a yeast vehicle; and b) a fusion protein expressed by the yeast vehicle, the fusion protein comprising: i) at least one cancer antigen or immunogenic domain thereof; and ii) a peptide linked to the N-terminus of the cancer antigen or immunogenic domain thereof, the peptide consisting of between two and six amino acid residues that are heterologous to the cancer antigen or immunogenic domain thereof, wherein the peptide stabilizes the expression of the fusion protein in the yeast vehicle or prevents posttranslational modification of the expressed fusion protein; wherein the amino acid residue at position one of the fusion protein is a methionine; wherein the amino acid residue at position two of the fusion protein is not a glycine or a proline; wherein none of the amino acid residues at positions 2-6 of the fusion protein is a methionine; and, wherein none of the amino acid residues at positions 2-5 of the fusion protein is a lysine or an arginine. 2. The composition of claim 1, wherein the peptide consists of six amino acid residues that are heterologous to the antigen. 3. The composition of claim 1, wherein the fusion protein comprises at least two or more cancer antigens or immunogenic domains thereof. 4. The composition of claim 1, wherein the cancer antigen is an antigen expressed by a cancer selected from the group consisting of: melanomas, squamous cell carcinoma, breast cancers, head and neck carcinomas, thyroid carcinomas, soft tissue sarcomas, bone sarcomas, testicular cancers, prostatic cancers, ovarian cancers, bladder cancers, skin cancers, brain cancers, angiosarcomas, hemangiosarcomas, mast cell tumors, primary hepatic cancers, lung cancers, pancreatic cancers, gastrointestinal cancers, renal cell carcinomas, hematopoietic neoplasias and metastatic cancers thereof. 5. The composition of claim 1, wherein the cancer antigen consists of a fusion protein construct comprising multiple domains, wherein each domain consists of a peptide from an oncoprotein, the peptide consisting of at least 4 amino acid residues flanking either side of and including a mutated amino acid that is found in the protein, wherein the mutation is associated with tumorigenicity. 6. The composition of claim 1, wherein the cancer antigen is wild-type or mutant protein encoded by a ras gene. 7. The composition of claim 6, wherein the ras gene is selected from the group consisting of: K-ras, N-ras and H-ras genes. 8. The composition of claim 1, wherein the cancer antigen is a Ras protein or immunogenic domain thereof containing single or multiple mutations. 9. The composition of claim 1, wherein the cancer antigen comprises at least one mutated Ras protein or immunogenic domain thereof comprising a mutation at position 12 of Ras as compared to a wild-type Ras. 10. The composition of claim 1, wherein the cancer antigen comprises at least one mutated Ras protein or immunogenic domain thereof comprising a mutation at position 61 of Ras as compared to a wild-type Ras. 11. The composition of claim 10, wherein the cancer antigen further comprises at least one mutated Ras protein or immunogenic domain thereof comprising a mutation at position 12 of Ras as compared to a wild-type Ras. 12. The composition of claim 1, wherein the cancer antigen comprises at least one fragment of at least 5-9 contiguous amino acid residues of a wild-type Ras protein containing amino acid position 12, 13, 59 or 61 relative to the wild-type Ras protein, wherein the amino acid residues at position 12, 13, 59 or 61 are mutated with respect to the wild-type Ras protein. 13. The composition of claim 1, wherein the cancer antigen comprises at least one peptide that is fused in frame with another mutated cancer antigen, wherein the peptide is selected from the group consisting of: a) a peptide comprising at least from positions 8-16 of SEQ ID NO:3, wherein the amino acid residue at position 12 with respect to SEQ ID NO:3 is mutated as compared to SEQ ID NO:3; b) a peptide comprising at least from positions 9-17 of SEQ ID NO:3, wherein the amino acid residue at position 13 with respect to SEQ ID NO:3 is mutated as compared to SEQ ID NO:3; c) a peptide comprising at least from positions 55-63 of SEQ ID NO:3, wherein the amino acid residue at position 59 with respect to SEQ ID NO:3 is mutated as compared to SEQ ID NO:3; and d) a peptide comprising at least from positions 57-65 of SEQ ID NO:3, wherein the amino acid residue at position 61 with respect to SEQ ID NO:3 is mutated as compared to SEQ ID NO:3. 14. The composition of claim 13, wherein the mutated cancer antigen is a Ras protein comprising at least one mutation relative to a wild-type Ras protein sequence. 15. The composition of claim 1, wherein the cancer antigen is a fusion protein comprising the following polypeptides, in any order: a) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the amino acid at position 61 is mutated as compared to a wild-type Ras; and b) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 12, wherein the amino acid at position 12 is mutated as compared to wild-type Ras; and c) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the amino acid at position 61 is mutated as compared to a wild-type Ras. 16. The composition of claim 1, wherein the cancer antigen is a fusion protein comprising the following polypeptides, in any order: a) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamine at position 61 is substituted with a leucine as compared to a wild-type Ras; and b) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 12, wherein the glycine at position 12 is substituted with a valine as compared to wild-type Ras; and c) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamine at position 61 is substituted with an arginine as compared to a wild-type Ras. 17. The composition of claim 1, wherein the cancer antigen is a fusion protein comprising the following polypeptides, in any order: a) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamine at position 61 is substituted with a leucine as compared to a wild-type Ras; and b) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 12, wherein the glycine at position 12 is substituted with a cysteine as compared to wild-type Ras; and c) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamine at position 61 is substituted with an arginine as compared to a wild-type Ras. 18. The composition of claim 1, wherein the cancer antigen is a fusion protein comprising the following polypeptides, in any order: a) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamine at position 61 is substituted with a leucine as compared to a wild-type Ras; and b) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 12, wherein the glycine at position 12 is substituted with an aspartic acid residue as compared to wild-type Ras; and c) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamine at position 61 is substituted with an arginine as compared to a wild-type Ras. 19. The composition of claim 1, wherein the cancer antigen is EGF-R. 20. The composition of claim 1, wherein the cancer antigen is MART1. 21. The composition of claim 1, wherein the cancer antigen is VHL (von Hippel's Lindau protein). 22. The composition of claim 1, wherein the cancer antigen is BCR-abl. 23. The composition of claim 1, wherein the cancer antigen is Muc-1. 24. The composition of claim 1, wherein the yeast vehicle is selected from the group consisting of a whole yeast, a yeast spheroplast, a yeast cytoplast, a yeast ghost, and a subcellular yeast membrane extract or fraction thereof. 25. The composition of claim 1, wherein the yeast vehicle is selected from the group consisting of a whole yeast and a yeast spheroplast. 26. The composition of claim 1, wherein the yeast vehicle is a whole yeast. 27. The composition of claim 1, wherein the yeast vehicle is a whole, killed yeast. 28. The composition of claim 1, wherein the yeast vehicle is from a yeast selected from the group consisting of: Saccharomyces, Schizosaccharomyces, Kluveromyces, Hansenula, Candida and Pichia. 29. The composition of claim 1, wherein the yeast vehicle is from Saccharomyces. 30. The composition of claim 1, wherein yeast vehicle is from Saccharomyces cerevisiae. 31. A composition, comprising: a) a yeast vehicle; and b) a fusion protein expressed by the yeast vehicle, the fusion protein comprising: i) at least one cancer antigen or immunogenic domain thereof expressed by the animal's cancer; and ii)a peptide linked to the N-terminus of the cancer antigen or immunogenic domain thereof, the peptide consisting of between two and six amino acid residues that are heterologous to the cancer antigen or immunogenic domain thereof, wherein the peptide stabilizes the expression of the fusion protein in the yeast vehicle or prevents posttranslational modification of the expressed fusion protein, and wherein the peptide does not negatively impact an immune response against the cancer antigen or immunogenic domain thereof; wherein the first six amino acids of the fusion protein consist of an amino acid sequence of M-X2-X3-X4-X5-X6; (1) wherein M is methionine; (2) wherein X2 is any amino acid except glycine, proline, lysine or arginine; (3) wherein X3 is any amino acid except methionine, lysine or arginine; (4) wherein X4 is any amino acid except methionine, lysine or arginine; (5) wherein X5 is any amino acid except methionine, lysine or arginine; and (6) wherein X6 is any amino acid except methionine. 32. The composition of claim 31, wherein X6 is a proline. 33. The composition of claim 31, wherein the peptide consists of an amino acid sequence of M-A-D-E-A-P (SEQ ID NO:1). 34. The composition of claim 31, wherein the fusion protein comprises at least two or more cancer antigens or immunogenic domains thereof. 35. The composition of claim 31, wherein the cancer antigen is an antigen expressed by a cancer selected from the group consisting of: melanomas, squamous cell carcinoma, breast cancers, head and neck carcinomas, thyroid carcinomas, soft tissue sarcomas, bone sarcomas, testicular cancers, prostatic cancers, ovarian cancers, bladder cancers, skin cancers, brain cancers, angiosarcomas, hemangiosarcomas, mast cell tumors, primary hepatic cancers, lung cancers, pancreatic cancers, gastrointestinal cancers, renal cell carcinomas, hematopoietic neoplasias and metastatic cancers thereof. 36. The composition of claim 31, wherein the cancer antigen consists of a fusion protein construct comprising multiple domains, wherein each domain consists of a peptide from an oncoprotein, the peptide consisting of at least 4 amino acid residues flanking either side of and including a mutated amino acid that is found in the protein, wherein the mutation is associated with tumorigenicity. 37. The composition of claim 31, wherein the cancer antigen is wild-type or mutant protein encoded by a ras gene. 38. The composition of claim 31, wherein the cancer antigen is EGF-R. 39. The composition of claim 31, wherein the cancer antigen is MART1. 40. The composition of claim 31, wherein the cancer antigen is VHL (von Hippel's Lindau protein). 41. The composition of claim 31, wherein the cancer antigen is BCR-abl. 42. The composition of claim 31, wherein the cancer antigen is Muc-1. 43. The composition of claim 31, wherein the yeast vehicle is selected from the group consisting of a whole yeast, a yeast spheroplast, a yeast cytoplast, a yeast ghost, and a subcellular yeast membrane extract or fraction thereof. 44. The composition of claim 31, wherein the yeast vehicle is selected from the group consisting of a whole yeast and a yeast spheroplast. 45. The composition of claim 31, wherein the yeast vehicle is a whole yeast. 46. The composition of claim 31, wherein the yeast vehicle is a whole, killed yeast. 47. The composition of claim 31, wherein the yeast vehicle is from a yeast selected from the group consisting of: Saccharomyces, Schizosaccharomyces, Kluveromyces, Hansenula, Candida and Pichia. 48. The composition of claim 31, wherein the yeast vehicle is from Saccharomyces. 49. The composition of claim 31, wherein yeast vehicle is from Saccharomyces cerevisiae. 50. A composition comprising: a) a yeast vehicle; and b) a fusion protein expressed by the yeast vehicle, the fusion protein comprising: i) at least one cancer antigen or immunogenic domain thereof, wherein the cancer antigen is a mutant protein encoded by a ras gene; and ii)a peptide linked to the N-terminus of the cancer antigen or immunogenic domain thereof, the peptide consisting of between two and six amino acid residues that are heterologous to the cancer antigen or immunogenic domain thereof, wherein the peptide stabilizes the expression of the fusion protein in the yeast vehicle or prevents posttranslational modification of the expressed fusion protein, and wherein the peptide does not negatively impact an immune response against the cancer antigen or immunogenic domain thereof; wherein the first six amino acids of the fusion protein consist of an amino acid sequence of M-X2-X3-X4-X5-X6; (1) wherein M is methionine; (2) wherein X2 is any amino acid except glycine, proline, lysine or arginine; (3) wherein X3 is any amino acid except methionine, lysine or arginine; (4) wherein X4 is any amino acid except methionine, lysine or arginine; (5) wherein X5 is any amino acid except methionine, lysine or arginine; and (6) wherein X6 is any amino acid except methionine. 51. The method of claim 50, wherein X6 is a proline. 52. The method of claim 50, wherein the peptide consists of an amino acid sequence of M-A-D-E-A-P (SEQ ID NO: 1). 53. The composition of claim 50, wherein the ras gene is selected from the group consisting of: K-ras, N-ras and H-ras genes. 54. The composition of claim 50, wherein the cancer antigen or immunogenic domain thereof contains single or multiple mutations. 55. The composition of claim 50, wherein the cancer antigen comprises at least one mutated Ras protein or immunogenic domain thereof comprising a mutation at position 12 of Ras as compared to a wild-type Ras. 56. The composition of claim 50, wherein the cancer antigen comprises at least one mutated Ras protein or immunogenic domain thereof comprising a mutation at position 61 of Ras as compared to a wild-type Ras. 57. The composition of claim 56, wherein the cancer antigen further comprises at least one mutated Ras protein or immunogenic domain thereof comprising a mutation at position 12 of Ras as compared to a wild-type Ras. 58. The composition of claim 50, wherein the cancer antigen comprises at least one fragment of at least 5-9 contiguous amino acid residues of a wild-type Ras protein containing amino acid position 12, 13, 59 or 61 relative to the wild-type Ras protein, wherein the amino acid residues at position 12, 13, 59 or 61 are mutated with respect to the wild-type Ras protein. 59. The composition of claim 50, wherein the cancer antigen comprises at least one peptide that is fused in frame with another mutated cancer antigen, wherein the peptide is selected from the group consisting of: a) a peptide comprising at least from positions 8-16 of SEQ ID NO:3, wherein the amino acid residue at position 12 with respect to SEQ ID NO:3 is mutated as compared to SEQ ID NO:3; b) a peptide comprising at least from positions 9-17 of SEQ ID NO:3, wherein the amino acid residue at position 13 with respect to SEQ ID NO:3 is mutated as compared to SEQ ID NO:3; c) a peptide comprising at least from positions 55-63 of SEQ ID NO:3, wherein the amino acid residue at position 59 with respect to SEQ ID NO:3 is mutated as compared to SEQ ID NO:3;and d) a peptide comprising at least from positions 57-65 of SEQ ID NO:3, wherein the amino acid residue at position 61 with respect to SEQ ID NO:3 is mutated as compared to SEQ ID NO:3. 60. The composition of claim 59, wherein the mutated cancer antigen is a Ras protein comprising at least one mutation relative to a wild-type Ras protein sequence. 61. The composition of claim 50, wherein the cancer antigen is a fusion protein comprising the following polypeptides, in any order: a) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the amino acid at position 61 is mutated as compared to a wild-type Ras; and b) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 12, wherein the amino acid at position 12 is mutated as compared to wild-type Ras; and c) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the amino acid at position 61 is mutated as compared to a wild-type Ras. 62. The composition of claim 50, wherein the cancer antigen is a fusion protein comprising the following polypeptides, in any order: a) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamine at position 61 is substituted with a leucine as compared to a wild-type Ras; and b) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 12, wherein the glycine at position 12 is substituted with a valine as compared to wild-type Ras; and c) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamine at position 61 is substituted with an arginine as compared to a wild-type Ras. 63. The composition of claim 50, wherein the cancer antigen is a fusion protein comprising the following polypeptides, in any order: a) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamine at position 61 is substituted with a leucine as compared to a wild-type Ras; and b) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 12, wherein the glycine at position 12 is substituted with a cysteine as compared to wild-type Ras; and c) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamine at position 61 is substituted with an arginine as compared to a wild-type Ras. 64. The composition of claim 50, wherein the cancer antigen is a fusion protein comprising the following polypeptides, in any order: a) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamine at position 61 is substituted with a leucine as compared to a wild-type Ras; and b) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 12, wherein the glycine at position 12 is substituted with an aspartic acid residue as compared to wild-type Ras; and c) a polypeptide comprising a mutated Ras protein or immunogenic domain thereof comprising position 61 of Ras, wherein the glutamine at position 61 is substituted with an arginine as compared to a wild-type Ras. 65. The composition of claim 50, wherein the yeast vehicle is selected from the group consisting of a whole yeast, a yeast spheroplast, a yeast cytoplast, a yeast ghost, and a subcellular yeast membrane extract or fraction thereof. 66. The composition of claim 50, wherein the yeast vehicle is selected from the group consisting of a whole yeast and a yeast spheroplast. 67. The composition of claim 50, wherein the yeast vehicle is a whole yeast. 68. The composition of claim 50, wherein the yeast vehicle is a whole, killed yeast. 69. The composition of claim 50, wherein the yeast vehicle is from a yeast selected from the group consisting of: Saccharomyces, Schizosaccharomyces, Kluveromyces, Hansenula, Candida and Pichia. 70. The composition of claim 50, wherein the yeast vehicle is from Saccharomyces. 71. The composition of claim 50, wherein yeast vehicle is from Saccharomzyces cerevisiae.